Research

No Applicants // Limit: 3 // Tickets Available: 3 

This NOFO announces the availability of funds and solicits applications from eligible entities to develop projects for hydrofluorocarbon (HFC) reclamation and innovative destruction technologies. Section 60109 of the Inflation Reduction Act (IRA) provided the EPA with $15 million for competitive grants for “reclaim and innovative destruction technologies” consistent with subsections (a) through (i) and subsection (k) of section 103 division S of Public Law 116-260 (42 U.S.C. 7675) (also known as the American Innovation and Manufacturing Act). Enacted in 2020, the American Innovation and Manufacturing (AIM) Act authorizes the EPA to address climate-damaging greenhouse gases (GHGs) called HFCs by: phasing down their production and consumption, maximizing reclamation and minimizing releases from equipment, and facilitating the transition to next-generation technologies through sector-based restrictions on HFCs. HFCs are potent GHGs commonly used in refrigeration and air conditioning equipment, as well as foams and many other applications. A global phasedown of HFCs is expected to avoid up to 0.5°C of global warming by 2100. There are hundreds of possible HFC compounds. The 18 HFCs listed as regulated substances by the AIM Act are some of the most commonly used HFCs and have high impacts as measured by the quantity emitted multiplied by their respective global warming potentials (GWPs). For more information on the AIM Act and its implementing regulations, please visit https://www.epa.gov/climate-hfcs-reduction.

Areas of Interest

The objectives of the HFC Reclaim and Innovative Destruction Grants, as described under Assistance Listing 66.047, are to support and contribute to addressing HFCs under the AIM Act by funding the following three project areas (listed order below does not indicate preference):
(1) Reclaim Technologies – pilot projects for new/better technologies to increase the reclamation of HFCs by expanding access to reclamation and improving the reclamation process;
(2) Reclaim Market Dynamics – programs or pilot projects for innovative strategies that address market dynamics to increase HFC reclamation by lowering barriers; or
(3) Innovative Destruction Technologies – pilot projects for innovative technologies or innovative deployment of technologies to destroy unusable and/or unwanted HFCs

 Limit: 2 // J.  Green (Environmental Science), L. Ikner (Environmental Science)

*Deadline note: Due to the competitive nature of this funding program, this selection process is running with an anticipated deadline.
We will inform all applicants of relevant updates in the guidelines, submission deadlines, and eligibility as soon as more information becomes available.

The Packard Fellowships for Science and Engineering Program invests in future leaders who can take risks, explore new frontiers in their fields of study, and follow uncharted paths that may lead to groundbreaking discoveries.

The Foundation established the Packard Fellowships for Science and Engineering to allow the nation's most promising early career professors to pursue their science and engineering research with few funding restrictions and limited paperwork requirements.

Competitive Proposals Will explain clearly in the nomination letter(s) why the investigator is creative, innovative and promising. The proposed research program has breakthrough potential and reflects that promise and a sense of adventure and creativity. Proposals should put the work and its significance in context of the larger field. And differentiates projects should be accessible to a group of very successful scientists from a diverse set of fields (i.e. stay away from field-specific jargon). Projects must have high impact referees that can emphasize the significance and impact of the “big idea” and how the fellowship will significantly impact the nominee’s career.

Eligibility:

• Candidates must be faculty members who are eligible to serve as principal investigators engaged in research in the natural and physical sciences or engineering and must be within the first three years of their faculty careers.
• Disciplines that will be considered include biology, chemistry, bio-medical engineering, physics, chemistry, mathematics, biology, astronomy, computer science, earth science, ocean science, and all branches of engineering. Candidates engaged in research in the social sciences will not be considered.
• Candidates must be faculty members in the first three years of their faculty careers, that is, whose initial appointment began no earlier than May 31, 2021, and no later than May 31, 2024.

Limit: 3 // PIs:
Y. Vitaliy (Aerospace and Mechanical Engineering)
B. Revil-Baudard (Materials Science and Engineering)
H. Rastgoftar (Aerospace and Mechanical Engineering)

The DEVCOM Army Research Lab seeks unclassified research proposals from Historically Black Colleges and Universities and Minority-Serving Institutions (HBCU/MI) under Broad Agency Announcement (FOA) W911NF-23-S-0001-0002 (hereafter referred to as the DEVCOM ARL BAA”) to establish an Army HBCU/MI Early Career Program (ECP) which embodies the high priority placed by the government on maintaining the leadership position of the United States in science by producing outstanding scientists and engineers and nurturing their continued development. Each award will support basic research contributing to Army modernization needs conducted by outstanding scientists and engineers beginning their careers at HBCU/MI institutions. ECP awards are funded by the Army to support early career scientists and engineers who show exceptional ability and promise for conducting basic research. This targeted opportunity is open to U.S. citizens, U.S. Nationals, or Lawful Permanent Residents of the U.S. who have held a tenure- track position at a covered educational institution for fewer than five years at the time applications are due in response to this special notice. Faculty at an institution of higher education which does not designate a faculty appointment as "tenure track" are eligible if that fact is so indicated in the proposal, and the supporting letter from the institute states that the faculty member submitting the proposal will be considered for a permanent appointment, or it is demonstrated that the faculty member is within five years of receiving his or her first competitively awarded federal research funding (as principal investigator), excluding funds secured during graduate school or postdoctoral training/fellowship and funds secured for training, fellowship, education, or career development. The objective of the ECP Award is to foster creative basic research in science and engineering; enhance development of outstanding early career investigators; and increase opportunities for early career investigators to pursue research in areas relevant to the Army. Proposals that do not meet these criteria for the Principal Investigator (PI) will be considered ineligible and not reviewed or considered for funding.

The eleven DEVCOM ARL competencies are:

•   Biological and Biotechnology Sciences

•   Electromagnetic Spectrum Sciences

•   Energy Sciences

•   Humans in Complex Systems

•   Mechanical Sciences

•   Military Information Sciences

•   Network, Cyber, and Computational Sciences

•   Photonics, Electronics, and Quantum Sciences

•   Sciences of Extreme Materials

•   Terminal Effects

•   Weapons Sciences

DEVCOM ARL plans to award up to eight (8) new HBCU/MI ECP grants at a total cost of $990,000 each over a duration of 5 years, with funding profile of $110,000 in year one, $165,000 in year two, $220,000 in year three, $330,000 in year four, and $165,000 in year five. Note this is more funding and longer duration than the typical ECP award specified in the DEVCOM ARL BAA.

No Applicants // Limit: 1 // Tickets Available: 1 

The purpose of this research NOFO is to follow a cohort of interstitial cystitis (IC) patients over time, define the demographic and clinical patterns of IC, and document its impact on the health of affected people. In addition, the focus of this NOFO will include translating the scientific knowledge on IC extracted from previously funded and other studies so it can be used to support public health action, including patient strategies for improving quality of life, provider awareness and education, and medical and self-management of IC; strengthen clinical, community, and public health linkages; and target groups disproportionately impacted by IC.

The estimated total funding (direct and indirect) for the first budget period (9/30/2024 to 9/29/2025) is $830,000. The estimated total funding (direct and indirect) for the entire performance period (9/30/2024 to 9/29/2029) is $4,150,000. The estimated award ceiling is $900,000 for the first 12-month budget period (9/30/2024 to 9/29/2025).

No applicants  // Limit: 1 // Tickets Available: 1 

The National Center for Advancing Translational Sciences (NCATS) will award Institutional Research Career Development (K12) programs through the Clinical and Translational Science Awards (CTSA). The purpose of this Funding Opportunity Announcement (FOA) is to encourage institutions to propose creative and innovative institutional research career development programs designed to prepare an outstanding heterogeneous pool of promising later stage postdoctoral fellows and junior faculty scholars in clinical and translational science who have made a commitment to independent research careers (i.e., tenure-track or equivalent faculty positions), and to facilitate their timely transition to more advanced support mechanisms, e.g., K08, K23, R01, R03, etc. Applicants must submit both a UM1 application to PAR-21-293: Clinical and Translational Science Award and a K12 application to this FOA.

This Funding Opportunity Announcement (FOA) allows appointment of Scholars (K12) proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

With this solicitation for the K12 application, a separate, companion FOA solicits applications for a required UM1 (PAR-21-293). A UM1 hub application without the required companion K12 application will not be reviewed. The required K12 application will only be awarded if the UM1 application is awarded. Initial and resubmission of K12 will be accepted concurrently or if the UM1 application is awarded.

The application must provide a specific plan describing the partnership between the UM1, the required K12 and any optional components. The applicant institution must be the UM1 applicant. The UM1 institution must have a strong and high-quality research program in the area(s) proposed under this K12 FOA and must have the requisite faculty, staff, potential scholars and facilities on site to conduct the proposed institutional program. In many cases, it is anticipated that the proposed program will complement other ongoing career development programs occurring at the applicant institution and that a substantial number of program faculty will have active research projects in which participating scholars may gain relevant experiences consistent with their research interests and goal.

The sponsoring institution must assure support for the proposed program. Appropriate institutional commitment to the program includes the provision of adequate staff, facilities, and educational resources that can contribute to the planned program.

The PD/PI should be an established investigator in the scientific area in which the application is targeted and capable of providing both administrative and scientific leadership to the development and implementation of the proposed program. The PD/PI will be responsible for the selection and appointment of trainees to the approved research training program, and for the overall direction, management, administration, and evaluation of the program. The PD/PI will be expected to monitor and assess the program and submit all documents and reports as required. The PD/PI has responsibility for the day to day administration of the program and is responsible for appointing members of the Advisory Committee (when applicable), using their recommendations to determine the appropriate allotment of funds.

Only one K12 application will be awarded if the UM1 application is awarded. If the UM1 is awarded and the initial K12 is not, the K12 application may be resubmitted. If the UM1 (A0) application is not awarded, then the K12 (A0) will not be awarded.

NCATS solicits the submission of one set of companion applications. With this FOA for the K12 application, a separate, companion FOA seeks applications for a required UM1 (PAR-21-293: Clinical and Translational Science Award). The UM1 and initial K12 applications must be submitted concurrently; a K12 application without the required companion UM1 application will not be reviewed. The required K12 application will only be awarded if the UM1 application is awarded. 

 Limit: 4 // Tickets Available: 3 // S. Yeo (Postdoctoral UACC)

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply.

This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFOs (PAR-23-287 or PAR-23-288).

Each eligible institution (defined as having a unique UEI number or NIH IPF number) may submit up to a combined total of four applications (one in Cancer Data Science, one in Cancer Control Science, one in Molecular/Precision Cancer Prevention, and one in Other Cancer Research) to any companion NOFO or any combination of companion NOFOs (PAR-23-286, PAR-23-287, and/or PAR-23-288).

No Applicants // Limit: 4 // Tickets Available: 4

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply.

This notice of funding opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-23-286).

Each eligible institution (defined as having a unique UEI number or NIH IPF number) may submit up to a combined total of four applications (one in Cancer Data Science, one in Cancer Control Science, one in Molecular/Precision Cancer Prevention, and one in Other Cancer Research) to any companion NOFO or any combination of companion NOFOs (PAR-23-286, PAR-23-287, and/or PAR-23-288).

No Applicants // Limit: 4 // Tickets Available: 4

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply.

This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-23-286).

This Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO.

The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Each eligible institution (defined as having a unique UEI number or NIH IPF number) may submit up to a combined total of four applications (one in Cancer Data Science, one in Cancer Control Science, one in Molecular/Precision Cancer Prevention, and one in Other Cancer Research) to any companion NOFO or any combination of companion NOFOs (PAR-23-286, PAR-23-287, and/or PAR-23-288).

No applicants // Limit: 5 // Tickets Available: 5

The University of Arizona Cancer Center (UACC) can nominate five applications for the Damon Runyon Clinical Investigator Award. 
For more information please contact: UACC-PreAward.

The Damon Runyon Clinical Investigator Award supports independent young physician-scientists conducting disease-oriented research that demonstrates a high level of innovation and creativity. The goal is to support the best young physician-scientists doing work aimed at improving the practice of cancer medicine.

The Clinical Investigator Award responds to three recognized realities:

• Though there has never been a more pressing need or more promising time for clinical cancer research, fewer young physicians enter this area of investigation every year.
• The number of institutions committed to training young physicians in the scientific discipline and methodologies of clinical investigation is critically low.
• The burden of medical school debt (averaging over $100,000) discourages many physicians from pursuing clinical investigation.

The Damon Runyon Cancer Research Foundation’s award offers solutions to these realities. The awardee will receive financial support for three years, as well as assistance with certain research costs such as the purchase of equipment. The Foundation will also retire up to $100,000 of any medical school debt still owed by the awardee.

The Clinical Investigator Award program is specifically intended to provide outstanding young physicians with the resources and training structure essential to becoming successful clinical investigators. The goal is to increase the number of physicians capable of moving seamlessly between the laboratory and the patient’s bedside in search of breakthrough treatments.